

## CME INFORMATION

### 2023 NEW YORK TRANSCATHETER VALVES SYMPOSIUM

December 7, 2023

New York, NY

#### **Target Audience**

The New York Transcatheter Valves Symposium has been designed to meet the educational needs of interventional cardiologists, invasive cardiologists, cardiothoracic surgeons, interventional radiologists, interventional fellows-in-training, nurses, technicians, and allied health care professionals who work in structural heart disease.

#### **Educational Goal**

The purpose of this educational activity is to provide new and emerging approaches in the diagnosis, management, and treatment of valvular and structural heart disease.

#### **Learning Objectives**

- Explain new technologies in the management of structural heart disease
- Describe indications, techniques, outcomes, and complications for transcatheter valve intervention in patients with native valve disease and bioprosthetic valve dysfunction
- Evaluate the rationale, challenges, and necessity of the heart team approach to valvular heart disease
- Discuss the barriers to care in patients with valvular heart disease with specific attention to current gaps in the timely delivery of percutaneous and surgical interventions

#### **Accreditation**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of *CMEsolutions* and Gaffney Events. The *CMEsolutions* is accredited by the ACCME to provide continuing medical education for physicians.

The *CMEsolutions* designates this live activity for a maximum of 7.75 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component and 75% passing on MOC test, enables the participant to earn up to 7.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### **Nursing Contact Hour Information**

This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. 7.75 Contact Hours

### **ASRT**

Approved by ASRT 9.5 Category A

### **FEES**

There are fees for participating in this activity.

### **PARTICIPATION REQUIREMENTS**

1. Read CME Information
2. Attend Sessions- credit given commensurate with attendance
3. Logon to the following URL: <https://online-med-edu.com/nytv/120720323/cme>
4. Complete evaluation, credit request form, MOC request, and download or print credit statement. MOC credit will appear in your ABIM account four weeks after successful completion of your request.

### **FACULTY AND DISCLOSURES**

*CMEsolutions* requires everyone in a position to control the content of this activity to disclose any relevant financial conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by *CMEsolutions* for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. *CMEsolutions* has mitigated all conflicts of interest prior to this educational activity.

#### ***Alexandre Abizaid, MD, PhD, FACC***

Director Interventional Cardiology at InCor, Sao Paulo  
Sao Paulo, SP, Brazil

Disclosed the following relevant financial relationships: Boston Scientific-Consultant

#### ***David H. Adams, MD***

Cardiac Surgeon-in-Chief, Department of Cardiovascular Surgery, Mount Sinai Health System  
New York, NY

Disclosed the following relevant financial relationships: Medtronic-National Co-PI of the Medtronic APOLLO FDA Pivotal Trial and The Medtronic CoreValve US Pivotal Trial; NeoChord-National Co PI NeoChord FDA Pivotal Trial; Abbott-National Co PI TRILUMINATE Pivotal Trial

#### ***Anita Asgar, MD, FACC***

Interventional Cardiologist, Montreal Heart Institute  
Montreal, Quebec, Canada

Disclosed the following relevant financial relationships: Abbott, Medtronic-Consultant, Advisor; Teleflex, Edwards Lifescience, W.L Gore-Consultant

***Vinayak N. Bapat, MD***

Chief of Cardiac Surgery, Abbott Northwestern and United Hospital  
Minneapolis, MN

Disclosed the following relevant financial relationships: Boston Scientific, Medtronic, Abbott, Anteris, Edwards-Consultant

***George D. Dangas, MD, PhD, MACC, MSCAI***

Professor of Cardiology & Vascular Surgery; Director, Cardiovascular Innovation, The Mount Sinai Hospital  
New York, NY

Disclosed the following relevant financial relationships: Daiichi-Sankyo-Researcher, Consultant

***Neil Fam, MD, MSc, FRCPC***

Cardiologist, St. Michael's Hospital  
Toronto, ON, Canada

Disclosed the following relevant financial relationships: VenusMedTech, Edwards, Abbott-Consultant

***Sunny Goel, MD, FACC, FSCAI***

Assistant Professor of Medicine, Cardiology, Mount Sinai Hospital  
Oceanside, NY

Has no relevant financial relationships to disclose.

***Kendra J. Grubb, MD, MHA, FACC***

Surgical Director, Structural Heart and Valve Center Emory University; Associate Professor, Surgery and Medicine, Emory University  
Atlanta, GA

Disclosed the following relevant financial relationships: Medtronic, Ancora-Consultant, Advisor, Speaker; Boston Scientific, Abbott-Advisor, Speaker; Edwards-Consultant

***Eberhard Grube, MD, MSCAI***

Head CIIC, University Hospital Bonn  
Bonn, Germany

Disclosed the following relevant financial relationships: Medtronic, Boston Scientific, HighLife, Jena Valve, Protebmbis-Consultant

***Rebecca T. Hahn, MD***

Director of Interventional Echocardiography; Professor of Medicine, New York-Presbyterian / Columbia University Medical Center  
New York, NY

Disclosed the following relevant financial relationships: Abbott Structural, Baylis Medical, Edwards Lifesciences, Medtronic and Philips Healthcare, Siemens Healthineers-Speaker

***Howard C. Herrmann, MD***

System Director and Section Chief for Interventional Cardiology, University of Pennsylvania  
Philadelphia, PA

Disclosed the following relevant financial relationships: Abbott, Boston Scientific, Edwards Lifesciences, Highlife, Innovalve, Medtronic, Vivasure-Researcher; Medtronic, Johnson and Johnson-Consultant

**Edwin C. Ho, MD**

Director, Structural Heart Imaging; Director, Echocardiography Lab; Co-Director, Structural Heart, Heart Valve Center, Montefiore Medical Center  
Bronx, NY

Disclosed the following relevant financial relationships: Edwards Lifesciences, Abbott, GE-Consultant; Neochord-Advisor; Philips-Researcher

**Amit Hooda, MD, FACC, FSCAI**

Assistant Professor, Department of Medicine, Cardiology, The Mount Sinai Hospital  
New York, NY

Has no relevant financial relationships to disclose.

**Samir Kapadia, MD, FSCAI**

Chairman, Dept. Cardiovascular Medicine, Professor of Medicine Director, Cleveland Clinic  
Cleveland, OH

Disclosed the following relevant financial relationships: Navigate- Ownership interest

**Sahil Khera, MD, MPH, FACP, FACC, FSCAI**

Interventional Director, Structural Heart Program, The Mount Sinai Hospital  
New York, NY

Disclosed the following relevant financial relationships: Medtronic- Consultant, Speaker, Proctor; Terumo, Abbott, EastEnd Medical-Consultant; Zoll-Speaker

**Annapoorna S. Kini, MD, MRCP, FACC**

Director, Cath Lab, The Mount Sinai Hospital  
New York, NY

Has no relevant financial relationships to disclose.

**Parasuram M. Krishnamoorthy, MD, FACC, FSCAI**

Associate Director, Structural Heart Program; Assistant Professor of Medicine, Division of Cardiology, Icahn School of Medicine at Mount Sinai  
New York, NY

Has no relevant financial relationships to disclose.

**Stamatios Lerakis, MD, PhD, FACC, FAHA, FASE, FSCCT, FSCMR, FASNC**

Professor and Director of Cardiovascular Imaging Program, Mount Sinai Heart  
New York, NY

Has no relevant financial relationships to disclose.

**Raj Makkar, MD, FACC**

Vice President of Cardiovascular innovation and Intervention, Cedars-Sinai Medical Center  
Los Angeles, CA

Disclosed the following relevant financial relationships: Abbott, Edwards Lifesciences, Boston Scientific-Researcher; Cordis, Medtronic-Consultant

***Pedro R. Moreno, MD, FACC***

Professor of Medicine, Cardiology Director of Quality, The Mount Sinai Hospital,  
New York, NY

Has no relevant financial relationships to disclose.

***Lucy M. Safi, DO, FACC, FASE, FSCAI***

Assistant Professor of Medicine (Cardiology), Mount Sinai Hospital

New York, NY

Disclosed the following relevant financial relationships: Medtronic, Abbott-Speaker

***Samin K. Sharma, MD, FACC, MSCAI***

Director, Mount Sinai Cardiovascular Clinical Institute; Director, Interventional Cardiology, Mount Sinai Health System; President, Mount Sinai Heart Network Anandi Lal Sharma Professor of Medicine, Cardiology, The Mount Sinai Hospital

New York, NY

Has no relevant financial relationships to disclose.

***Gagan Singh, MD, FACC, FSCAI***

Physician, UC Davis Medical Center

Sacramento, CA

Disclosed the following relevant financial relationships: Abbott Structural Heart, Boston Scientific-Consultant, Speaker; Philips-Consultant, Advisor, Speaker

***Paul Sorajja, MD, FACC, FSCAI***

Senior Consulting Cardiologist, Allina Health

Minneapolis, MN

Disclosed the following relevant financial relationships: 4C Medical, Abbott Structural, Edwards Lifesciences, Medtronic, Foldax-Consultant

***Gregg W. Stone, MD, FACC, MSCAI***

Director of Academic Affairs, Mount Sinai Heart Health System, Professor of Medicine, Cardiology; Professor of Population Health Sciences and Policy, Mount Sinai Health System

New York, NY

Disclosed the following relevant financial relationships: Medtronic, Pulnovo, Infraedx, Abiomed, Abbott, Amgen-Speaker; Daiichi Sankyo, CorFlow, Apollo Therapeutics, Cardiomech, Ablative Solutions, Valfix, TherOx, Robocath, Heartflow, Miracor, Neovasc, Ancora, Vectorious, Elucid Bio, Occlutech, Impulse Dynamics, Adona Medical. Millennia Biopharma, Oxitope-Consultant; Ancora, Cagent, Applied Therapeutics, Biostar Family of Funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter-Stocks

***Gilbert H. L. Tang, MD, MSc, MBA, FRCSC, FACC, FSCAI***

Surgical Director, Structural Heart Program, Mount Sinai Health System

New York, NY

Disclosed the following relevant financial relationships: Abbott Structural Heart, Medtronic-Consultant, Advisor, Speaker; JenaValve-Advisory; NeoChord-Consultant; Siemens Healthineers-Speaker

**Planner Disclosures**

No member of *CMEsolutions* or Gaffney Events has any relevant financial relationships to disclose regarding this activity.

**Off-label Use**

This activity may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA. Please consult the prescribing information for each product.

**Commercial Support**

Boston Scientific  
Abbott

**Privacy Policy**

*CMEsolutions* Privacy and Confidentiality Policy: [www.online-med-edu.com/privacypolicy.pdf](http://www.online-med-edu.com/privacypolicy.pdf)  
*CMEsolutions* can be contacted at [info@cmesolutions.org](mailto:info@cmesolutions.org).